Why Health Care Costs More When Ownership Gets Closer to the Patient

Hatched by Ben H.

Jun 08, 2026

10 min read

2 views

73%

The strange economics of being closer to care

Why would a primary care practice cost more when it becomes more integrated, more organized, and, in theory, more efficient? And why does a kidney care company grow by proving it can lower costs precisely when it takes on the most complex, highest-risk patients?

That tension points to a deeper truth about American health care: cost is not only a function of medicine, but of power. The system does not simply reward better care. It often rewards whoever controls the point of access, the billing relationship, and the patient referral stream.

That is why two facts that seem unrelated actually belong in the same sentence. On one side, hospital-affiliated primary care practices receive higher reimbursement than independent practices. On the other, value-based kidney care expands by managing chronic disease more intelligently and promising lower unnecessary spending. Together they reveal a system split between two competing logics: fee-for-service consolidation and outcome-based coordination.

The first logic says: own more of the pipeline, and the money follows. The second says: reduce avoidable harm, and the savings should follow. The battle between these logics is not theoretical. It determines where patients go, who gets paid, and whether care becomes more fragmented or more coherent.

The hidden premium on control

The reimbursement gap between hospital-affiliated and independent primary care practices is not just a billing detail. It is a clue about how the system values organizational proximity to the hospital. Once a practice becomes part of a hospital network, the same visit can be priced differently, even if the clinician, the patient, and the diagnosis barely change.

Think of it like two coffee shops selling the same cup of coffee. One sits inside a luxury hotel, the other in a neighborhood storefront. The coffee is similar, but the location changes what people are willing or required to pay. In health care, affiliation itself becomes a multiplier.

This matters because it creates a perverse gravitational pull. Independent practices struggle to survive under lower reimbursement. Hospitals can justify acquiring them as a way to stabilize access, but the acquisition also raises the price of routine care. The result is that more of the system becomes owned by larger entities, and the price of basic care rises with it.

The deeper mechanism is not greed in a cartoonish sense. It is the economics of anchoring. Once the hospital becomes the anchor institution, the system routes more patient volume, more negotiation leverage, and more billing power through it. The patient may never see this structure, but the payer does, and ultimately the premium works its way back into premiums, deductibles, and public spending.

In health care, proximity to the hospital can become a proxy for market power, not necessarily for better outcomes.

That is the first half of the puzzle: the system rewards control over the pathway, even when that control does not clearly improve the care itself.

Why value-based kidney care is different

Kidney care sits in a very different part of the system. Chronic kidney disease and end-stage kidney disease are expensive, relentless, and highly sensitive to coordination failures. A missed medication, a delayed referral, or poor dialysis planning can snowball into hospitalization, emergency care, and worse outcomes.

This is where value-based care has a real chance to matter. If a care model can keep people stable, intervene earlier, and reduce unnecessary medical spending, then success is not measured by volume but by avoided catastrophe. That is why a partnership expanding across multiple states is significant. It suggests scale without the usual fee-for-service logic of simply adding more encounters.

Kidney care is especially revealing because it shows the difference between treating transactions and managing trajectories. A transaction model pays for each dialysis session, each specialist visit, each admission. A trajectory model asks a different question: what combination of care management, patient support, and early intervention keeps the patient healthier over time?

The contrast matters because chronic kidney disease is not a single event. It is a long descent, often shaped by diabetes, hypertension, medication adherence, transportation barriers, nutrition, and access to nephrology. A fragmented system turns this into a series of expensive surprises. A coordinated system tries to make those surprises less frequent.

This is why value-based kidney care can grow even while the reimbursement system elsewhere rewards consolidation. It is not merely a business strategy. It is an attempt to redesign the unit of value in health care from the visit to the outcome.

Two competing engines: margin capture versus problem solving

These examples expose two different engines inside health care.

1. Margin capture

Margin capture is the instinct to increase revenue by controlling where care happens and how it is billed. Hospital affiliation, acquisition, network expansion, and site-of-service pricing all belong here. The goal is not necessarily bad care. In many cases, the care may be excellent. But the financial logic depends on owning the funnel.

This engine tends to reward scale, integration, and bargaining leverage. It thrives when the system pays more for complexity, referrals, and institutional placement.

2. Problem solving

Problem solving is the instinct to reduce the need for expensive care by preventing deterioration. Value-based kidney care belongs here. It looks for the highest-risk patients, wraps services around them, and tries to prevent unnecessary admissions and late-stage crises.

This engine rewards coordination, data, patient engagement, and clinical discipline. It thrives when the payment model gives providers a reason to care about downstream outcomes rather than just upstream encounters.

The tension between these engines explains much of the confusion in modern health care policy. People often ask whether the system is becoming more efficient or more expensive. The answer is often both, depending on which engine is getting stronger in a particular region or specialty.

A hospital system can become more integrated and still make routine care more expensive. A value-based kidney care organization can expand rapidly and still lower total cost. That is not a contradiction. It is evidence that efficiency and pricing power are not the same thing.

The real question: who benefits when care gets organized?

The popular assumption is that more organization means better care and lower cost. Sometimes it does. But in health care, organization is politically neutral and economically charged. The same structure that improves coordination can also create pricing power.

That is why the central question is not whether health care is integrated. It is: integrated for what purpose, and at whose expense?

If integration mainly improves referral capture, then patients may pay more for ordinary visits while the institution grows stronger. If integration mainly improves care navigation, then patients may benefit through fewer hospitalizations and smoother chronic disease management. The label looks the same, but the economics differ radically.

Imagine two road systems. One builds more toll booths near the city center and charges more because everyone must pass through. The other redesigns the roads to reduce traffic jams and accidents. Both are forms of organization. Only one is truly solving the transportation problem.

Health care keeps confusing these two. We celebrate size when it produces a more powerful organization, then call it quality improvement. But quality should be judged by whether the patient’s path becomes simpler, safer, and less expensive over time.

This is especially important in chronic disease. Patients with kidney disease do not need more touchpoints for their own sake. They need the right touchpoints at the right time, with the right incentives behind them. If the system is organized around billing, the patient experiences complexity. If it is organized around outcomes, the patient experiences continuity.

The most expensive health care systems are often the ones that are best organized around revenue, not around recovery.

A practical framework: the three questions of care design

To tell the difference between healthy coordination and expensive consolidation, use three questions.

1. Does the model reduce avoidable complexity for the patient?

Good care design makes it easier to get the right help without bouncing among disconnected offices. For a patient with kidney disease, that could mean coordinated medication review, nutrition support, timely specialist access, and clearer planning before the disease worsens.

If the system adds layers of administration but the patient still has to navigate everything alone, the organization is mostly internal, not clinical.

2. Does the model shift incentives toward prevention?

A model should make it financially rational to prevent hospitalizations, not merely to bill for them. If a provider earns more by doing more procedures or by being attached to a hospital site, then prevention will always be a secondary goal.

Value-based kidney care works only when the downside of poor outcomes is real enough to change behavior. Otherwise, it becomes a slogan attached to an old payment structure.

3. Does the model create accountability for total cost, not just local revenue?

A practice may look efficient from the inside while driving up spending elsewhere. A hospital-affiliated primary care office can receive higher reimbursement even if the care quality is unchanged. That means the true cost must be measured across the entire episode, not at the office door.

In chronic disease, the relevant question is not how much one visit costs. It is how much the full care journey costs over time, including admissions, specialist use, emergency visits, and long-term disability.

This framework reveals an uncomfortable truth. Many “innovations” are really just new ways to shift the bill. Real innovation changes the bill and the trajectory.

What this means for patients, employers, and policymakers

For patients, the lesson is to be suspicious of the word integration when it is used without a clear outcome. More logos on the building do not automatically mean better care. Ask whether the model reduces handoffs, prevents crises, and helps you understand your next step.

For employers and payers, the lesson is to separate price from performance. Hospital affiliation may be associated with higher reimbursement, but higher price is not the same as higher value. Purchasers should demand data on admissions avoided, dialysis starts delayed, emergency visits reduced, and patient experience improved.

For policymakers, the key task is to stop rewarding ownership changes as though they were clinical progress. If independent primary care is systematically underpaid while hospital systems are overpaid for the same service, consolidation will continue regardless of whether it helps patients. Payment design is not a technical detail. It is the architecture of the market.

For health systems, the challenge is even harder. If you want to grow while staying genuinely value-based, you must prove that scale is serving outcomes, not merely expanding the billing base. In other words, growth should be a byproduct of better coordination, not a substitute for it.

Key Takeaways

Ask who controls the care pathway. When ownership and reimbursement cluster around hospitals, costs often rise even if the clinical service stays the same.
Separate coordination from consolidation. A practice can be more organized without being more efficient. Look for evidence of better outcomes, not just larger networks.
Measure total cost over time. Especially in chronic disease, the real question is not the price of one visit but the cost of the entire patient journey.
Reward prevention, not just activity. Models that reduce hospitalizations, emergency visits, and late-stage crises deserve preference over those that simply increase volume.
Use the three questions framework. Does the model reduce patient complexity, shift incentives toward prevention, and create accountability for total cost?

The deeper lesson: health care is a fight over what counts as value

At first glance, hospital-affiliated primary care reimbursement and value-based kidney care seem like separate stories. One looks like a pricing anomaly, the other like a care innovation. But together they expose the central conflict in American medicine: is value located in ownership or in outcomes?

If value lives in ownership, then health care becomes a contest to control the most lucrative settings. If value lives in outcomes, then the system must pay for coordination, prevention, and patient stability. Those are not just different business models. They are different moral visions of what medicine is for.

The real challenge is that health care often praises the language of care while paying for the logic of control. That is why consolidation can feel inevitable and value-based care can feel fragile. Yet the future of medicine will depend on choosing between them more consciously.

The most important question is not whether health care gets bigger. It is whether it gets better at making patients less dependent on the system in the first place. That is a very different kind of power, and a far more useful one.